Compare EZRA & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EZRA | CDT |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | 40 | 6 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 22.1M |
| IPO Year | N/A | N/A |
| Metric | EZRA | CDT |
|---|---|---|
| Price | $0.17 | $2.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 82.4K |
| Earning Date | 05-14-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.37 |
| 52 Week High | $0.39 | $11.00 |
| Indicator | EZRA | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 42.94 |
| Support Level | $0.17 | $1.44 |
| Resistance Level | $0.23 | $2.48 |
| Average True Range (ATR) | 0.02 | 0.61 |
| MACD | -0.00 | -0.34 |
| Stochastic Oscillator | 8.22 | 1.47 |
Reliance Global Group Inc operates as a holding company that acquires, owns, and actively manages insurance and technology-focused businesses. The company focuses on growing by pursuing acquisition strategies initially, and focuses on wholesale and retail insurance agencies. Its primary move is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations. The Company operates as a single operating segment, the Insurance Segment, earning its revenues from insurance commissions.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.